Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
The BioIndustry Association (BIA) board has elected Edward Hodgkin as its new Chairman, effective 30 October 2013. Dr Hodgkin succeeds Mr Tim Edwards, who will formally step down at the October Board meeting following three years as BIA Chairman. Mr Edwards will remain a member of the BIA Board.
Edward Hodgkin has been a non-executive director of the BIA since 2010 and serves as a member of the BIA’s Executive Committee. He is a Partner with Syncona Partners, where his role is to create and lead new life science ventures. Prior to joining Syncona in April 2013, he was CEO of Biotica Technology Ltd, a Cambridge therapeutics company, from 2007 to 2012. Trained as a chemist, Ed has served in a variety of scientific, business and management roles in biotech and pharmaceutical companies in the US and UK over a career of more than 20 years.
Tim Edwards, outgoing Chairman of the BIA, said:
“I am delighted that Ed has been elected as the new Chairman of the BIA. His experience in the UK life sciences sector will be of great benefit to the organisation and its members. The BIA continues to be the leading advocacy group for the UK’s innovative bioscience companies of all sizes, and I thank Steve and his team for all their work on behalf of our members.”
Edward Hodgkin, new Chairman of the BIA, said:
“While our members face many challenges, not least being access to capital, there is a fantastic opportunity to put life sciences at the forefront of the nation’s recovering economy. Government, private enterprise and the public sector are aligned in this ambition, and the BIA is playing a central role in facilitating that.”
Steve Bates, Chief Executive of the BIA, said:
“I would like to thank Tim for his work on behalf of the whole BIA, in particular his championing of innovative forms of funding like Citizens Innovation Funds. I welcome Ed to his new role and look forward to working even more closely with Ed, building on our excellent relationship established through his current role on the BIA Executive and Board. On a personal note I’d like to thank Tim for his help and guidance to me in my first year in the job, and for staying in the chair an extra year to help me bed into my role.”
As Chairman designate, Dr Hodgkin will chair the BIA’s CEO and Investor Forum on 11 July.
For further information, please contact Robert Winder, Head of Communications, rwinder@bioindustry.org, 020 7630 2191; mobile 07825 942 934.
Photo of Ed Hodgkin
A high resolution image of Ed Hodgkin is available from http://bia.me/BIAEdHodgkin
Syncona Partners
Syncona Partners LLP was founded in 2012 and operates as an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to significantly impact the healthcare market of the future. Syncona is an investor that can take the long view when necessary, able to concentrate investment into opportunities as technology is validated. Syncona is an independent subsidiary of the Wellcome Trust who invested the initial £200 million capitalisation. Syncona Partners provides financial resources to individuals and companies to advance the Wellcome Trust’s vision of achieving extraordinary improvements in human and animal health by supporting the brightest minds in biomedical research and the medical humanities. http://www.synconapartners.com/
BIA CEO and Investor Forum
The BIA’s annual CEO and Investor Forum is an invitation only event which will be held on 10-11 July at Down Hall, Hatfield Heath. http://bit.ly/BIACEO2013
BioIndustry Association
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives. For further information, please go to www.bioindustry.org
Help employers find you! Check out all the jobs and post your resume.
